TEPMETKO is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping …

Feb 21, 2024 · Tepmetko is an oral (taken by mouth) kinase inhibitor that may be used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body …

TEPMETKO® (tepotinib) is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that: whose tumors have an abnormal mesenchymal epithelial transition …

TEPMETKO is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 …

Tepotinib, sold under the brand name Tepmetko, is an anti-cancer medication used for the treatment of adults with non-small cell lung cancer (NSCLC). [4] [5] [8]

Apr 21, 2025 · Overview: Tepmetko is used to treat certain types of non-small-cell lung cancer. It helps stop certain cancer cells from growing and multiplying. Common side effects include fluid...

Jun 1, 2023 · Tepmetko (tepotinib) is a medication that’s used for adults with metastatic non-small cell lung cancer (NSCLC) with certain mutations in the MET gene. This medication is …

On February 15, 2024, the Food and Drug Administration granted traditional approval to tepotinib (Tepmetko, EMD Serono, Inc.) for adult patients with metastatic non-small cell lung cancer …

Tepotinib is a targeted therapy that blocks a protein called MET, which helps cancer cells grow and spread. This treatment is specifically designed for patients whose cancer has a MET exon …

Medscape - Non-small cell lung cancer dosing for Tepmetko (tepotinib), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and …